Malin (MLC) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
26 Feb, 2026Executive summary
Estimated intrinsic equity value per share was €9.21 at 31 December 2025 and €9.24 at 23 February 2026, reflecting updated valuations and milestone progress.
Major leadership changes announced: CEO and Company Secretary Fiona Dunlevy to depart, with Non-Executive Chair Liam Daniel becoming Executive Chair and Andrea Stafford appointed as Company Secretary.
The company has transitioned to a new phase following the divestment of Poseida and a significant capital return to shareholders.
Financial highlights
Aggregate fair value of investee companies was €27.0 million at 31 December 2025, down from €133.5 million at 31 December 2024, mainly due to the Poseida divestment and valuation revisions.
Corporate cash balance was €12.9 million at 31 December 2025, compared to €62.1 million at 31 December 2024, primarily due to a €150 million capital return in March 2025.
Recurring corporate cash operating spend for 2025 was €2.1 million, down from €2.4 million in 2024.
Outlook and guidance
Board remains focused on maximizing shareholder returns from remaining investee interests, including contingent value rights and milestone payments.
Further clarity on Viamet's regulatory progress expected in the second half of 2026.
Latest events from Malin
- Intrinsic equity value was €41.3M on 30 June 2025, with €13.7M in cash.MLC
H1 20258 Sep 2025 - Cash surges to €62.9m post-CG Oncology sale; €45m capital return planned for shareholders.MLC
H1 202413 Jun 2025 - Major divestments drove a €150m capital return and record cash reserves for Malin in 2024.MLC
H2 20246 Jun 2025